Does Rallies show Form 4 insider transactions for KPRX?

Yes. Rallies tracks KPRX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is KPRX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for KPRX. It does not provide personalized investment advice.

KPRX (Kiora Pharmaceuticals, Inc. Common Stock) Stock Analysis - Insider Trades

Kiora Pharmaceuticals, Inc. Common Stock (KPRX) is a publicly traded Healthcare sector company. As of May 21, 2026, KPRX trades at $2.64 with a market cap of $11.12M and a P/E ratio of -1.01. KPRX moved +0.40% today. Year to date, KPRX is +25.71%; over the trailing twelve months it is -15.33%. Its 52-week range spans $1.76 to $4.18. Analyst consensus is buy with an average price target of $12.00. Rallies surfaces KPRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading KPRX stock inside the company?

Recent KPRX insider activity includes Stengone Carmine N. bought 1.25K, Shapiro Aron bought 3.00K, Walters-Hoffert Lisa bought 1.25K, TYLE PRAVEEN bought 5.00K, and Tosca Melissa bought 2.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

KPRX Key Metrics

Key financial metrics for KPRX
Metric	Value
Price	$2.64
Market Cap	$11.12M
P/E Ratio	-1.01
EPS	$-2.60
Dividend Yield	0.00%
52-Week High	$4.18
52-Week Low	$1.76
Volume	0
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-10.84M
Gross Margin	0.00%

Recent KPRX Insider Trades

Stengone Carmine N. bought 1.25K (~$4.60K) on Sep 11, 2024.
Shapiro Aron bought 3.00K (~$10.80K) on Sep 10, 2024.
Walters-Hoffert Lisa bought 1.25K (~$4.83K) on Aug 19, 2024.
TYLE PRAVEEN bought 5.00K (~$19.80K) on Aug 19, 2024.
Tosca Melissa bought 2.00K (~$6.42K) on Aug 14, 2024.

Latest KPRX News

Kiora Reports No Serious Adverse Events in Phase 1 KIO-301 Study, Initiates Phase 2 Trial — Apr 14, 2026
Kiora Pharmaceuticals Secures $24 Million Private Placement Led by Perceptive Advisors — Apr 7, 2026
Kiora Pharmaceuticals CDO to Resign April 17; Phase 2 100µg Cohort Initiated — Apr 2, 2026
Kiora Advances Two Phase II Trials, Secures $110M Asia Option and $17.1M Cash — Mar 25, 2026

KPRX Analyst Consensus

1 analysts cover KPRX: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $12.00.

Common questions about KPRX

Who is trading KPRX stock inside the company?: Recent KPRX insider activity includes Stengone Carmine N. bought 1.25K, Shapiro Aron bought 3.00K, Walters-Hoffert Lisa bought 1.25K, TYLE PRAVEEN bought 5.00K, and Tosca Melissa bought 2.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for KPRX?: Yes. Rallies tracks KPRX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is KPRX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for KPRX. It does not provide personalized investment advice.